Christine S. Breves
Christine S. Breves's purchase track record
Christine S. Breves has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/17/2023 | RXO | $101K | +8.0% | +3.0% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sylvamo Price Targets Lowered by BofA and Truist. Bank of America and Truist Securities recently lowered their price targets for Sylvamo, citing updated outlooks. While BofA maintains a Neutral rating with a $42 target, Truist keeps a Buy rating but reduced its target to $40. These adjustments place the new targets below the current average analyst estimate of $50.40, reflecting a more cautious view on the company's near-term valuation.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RXO Stock Gains as C.H. Robinson Deal Lifts Analyst Targets. RXO Inc. is in focus after the C.H. Robinson deal anchored higher analyst price targets, with Truist Securities raising its target to $30. This development comes alongside broader transport sector discussions regarding diesel prices and small-cap valuation questions. The stock is currently trading near the top of its 52-week range, reflecting recent momentum driven by these fundamental updates.
Transaction History
| MPLX | ▲ Buy | Grant | 219 | $0 | 8/14/2026 | View on chart |
| MPLX | ▲ Buy | Grant | 277 | $0 | 5/15/2026 | View on chart |
| SLVM | ▲ Buy | Grant | 3,876 | $150K | 5/15/2026 | View on chart |
| MPLX | ▲ Buy | Grant | 2,247 | $0 | 4/30/2026 | View on chart |
| MPLX | ▲ Buy | Grant | 218 | $0 | 2/17/2026 | View on chart |
| RXO | ▲ Buy | Option Exercise | 7,745 | $0 | 1/2/2026 | View on chart |
| MPLX | ▲ Buy | Grant | 230 | $0 | 11/14/2025 | View on chart |
| MPLX | ▲ Buy | Grant | 214 | $0 | 8/15/2025 | View on chart |
| MPLX | ▲ Buy | Grant | 201 | $0 | 5/16/2025 | View on chart |
| SLVM | ▲ Buy | Grant | 2,655 | $150K | 5/15/2025 | View on chart |
| MPLX | ▲ Buy | Grant | 2,481 | $0 | 5/1/2025 | View on chart |
| MPLX | ▲ Buy | Grant | 192 | $0 | 4/1/2025 | View on chart |
| MPLX | ▲ Buy | Grant | 145 | $0 | 2/14/2025 | View on chart |
| MPLX | ▲ Buy | Grant | 642 | $0 | 1/2/2025 | View on chart |
| RXO | ▲ Buy | Option Exercise | 8,045 | $0 | 1/2/2025 | View on chart |
| MPLX | ▲ Buy | Grant | 150 | $0 | 11/15/2024 | View on chart |
| MPLX | ▲ Buy | Grant | 699 | $0 | 10/1/2024 | View on chart |
| MPLX | ▲ Buy | Grant | 131 | $0 | 8/16/2024 | View on chart |
| MPLX | ▲ Buy | Grant | 729 | $0 | 7/1/2024 | View on chart |
| SLVM | ▲ Buy | Grant | 1,779 | $125K | 5/16/2024 | View on chart |
| MPLX | ▲ Buy | Grant | 117 | $0 | 5/13/2024 | View on chart |
| MPLX | ▲ Buy | Grant | 756 | $0 | 4/1/2024 | View on chart |
| MPLX | ▲ Buy | Grant | 107 | $0 | 2/14/2024 | View on chart |
| RXO | ▲ Buy | Option Exercise | 11,537 | $0 | 1/3/2024 | View on chart |
| MPLX | ▲ Buy | Grant | 852 | $0 | 1/2/2024 | View on chart |
| RXO | ▲ Buy | Open Market | 5,100 | $101K | 11/17/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 93 | $0 | 11/13/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 890 | $0 | 10/2/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 65 | $0 | 8/14/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 809 | $0 | 7/3/2023 | View on chart |
| SLVM | ▲ Buy | Grant | 5,334 | $0 | 5/16/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 47 | $0 | 5/15/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 791 | $0 | 4/3/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 28 | $0 | 2/14/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 844 | $0 | 1/3/2023 | View on chart |
| RXO | ▲ Buy | Option Exercise | 1,848 | $0 | 1/3/2023 | View on chart |
| MPLX | ▲ Buy | Grant | 405 | $0 | 11/30/2022 | View on chart |
| SLVM | ▲ Buy | Grant | 2,623 | $0 | 5/16/2022 | View on chart |
| SLVM | ▲ Buy | Grant | 2,809 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MPLX Units Draw Income Focus as Morgan Stanley Adjusts Target
MPLX units recently gained ground as the broader market dipped, highlighting the partnership's resilient profile. The company's high dividend yield continues to attract income-focused investors, featuring in several recent reports on top-paying energy stocks. Meanwhile, Morgan Stanley maintained its equal-weight stance on the units, adjusting its price target amid the market's recent performance.
MPLX Units Draw Income Focus as Morgan Stanley Adjusts Target. MPLX units recently gained ground as the broader market dipped, highlighting the partnership's resilient profile. The company's high dividend yield continues to attract income-focused investors, featuring in several recent reports on top-paying energy stocks. Meanwhile, Morgan Stanley maintained its equal-weight stance on the units, adjusting its price target amid the market's recent performance.